Lysophosphatidic acid receptors stimulate a Galpha(12/13)/RhoA-dependent gene transcription program involving the
serum response factor (SRF) and its coactivator and oncogene, megakaryoblastic
leukemia 1 (MKL1). Inhibitors of this pathway could serve as useful
biological probes and potential
cancer therapeutic agents. Through a transcription-based high-throughput serum response element-
luciferase screening assay, we identified two small-molecule inhibitors of this pathway. Mechanistic studies on the more potent
CCG-1423 show that it acts downstream of Rho because it blocks SRE.L-driven transcription stimulated by Galpha(12)Q231L, Galpha(13)Q226L, RhoA-G14V, and RhoC-G14V. The ability of
CCG-1423 to block transcription activated by MKL1, but not that induced by SRF-VP16 or
GAL4-VP16, suggests a mechanism targeting MKL/SRF-dependent transcriptional activation that does not involve alterations in
DNA binding. Consistent with its role as a Rho/SRF pathway inhibitor,
CCG-1423 displays activity in several in vitro
cancer cell functional assays.
CCG-1423 potently (<1 mumol/L) inhibits
lysophosphatidic acid-induced
DNA synthesis in PC-3
prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing
melanoma lines (A375M2 and SK-Mel-147) at nanomolar concentrations, it is less active on related lines (A375 and SK-Mel-28) that express lower levels of Rho. Similarly,
CCG-1423 selectively stimulates apoptosis of the
metastasis-prone, RhoC-overexpressing
melanoma cell line (A375M2) compared with the parental cell line (A375).
CCG-1423 inhibited Rho-dependent invasion by PC-3
prostate cancer cells, whereas it did not affect the Galpha(i)-dependent invasion by the SKOV-3
ovarian cancer cell line. Thus, based on its profile,
CCG-1423 is a promising lead compound for the development of novel pharmacologic tools to disrupt transcriptional responses of the Rho pathway in
cancer.